RNTX — Rein Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Aileron Therapeutics Says Appointed Timothy Cunningham As Interim CFO
Aileron Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Aileron Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Aileron Therapeutics Reports Closing Of Underwritten Registered Direct Offering Of Up To About $40 Million
Brief: Muneer Satter Reports 4.9% Stake In Aileron Therapeutics As Of April 2, 2024 - SEC Filing
Aileron Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Aileron Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Aileron Therapeutics On Feb 29 Got Letter From Nasdaq That Co Has Regained Compliance For Continued Listing On Nasdaq
Brief: Aileron Therapeutics Files Prospectus For Resale Of Up To 7.1 Million Shares By Selling Stockholders - SEC Filing
Aileron Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Aileron Therapeutics Inc expected to post a loss of 86 cents a share - Earnings Preview
Aileron Therapeutics Inc expected to post a loss of 86 cents a share - Earnings Preview
Brief: Aileron Therapeutics Inc - On February 16, 2023, Board Determined To Reduce Company's Remaining Workforce From Nine To Three Employees
U.S. STOCKS ON THE MOVE-VerifyMe, Molson Coors, Sigma Lithium
Aileron hits record low after ending chemoprotection drug trial
Aileron slides after ending chemoprotection drug trial
Brief: Aileron Therapeutics Announces Termination Of Phase 1B Breast Cancer Chemoprotection Trial
Brief: Aileron Therapeutics Regains Compliance With Nasdaq Listing Requirements
Brief: Aileron Therapeutics Announces A 1-For-20 Reverse Stock Split